Novo Nordisk has started testing a hitherto-unknown app for people's phones which will help diabetes patients find their recommended doses based on their blood sugar levels and the insulin doses that they have already ingested, according to a report for the database Clinical Trials, which gathers info on clinical trials.
The name of the Mobile App is Doseguide, and Novo Nordisk tells MedWatch that this particular app was developed internally within the Danish pharmaceutical company. Novo Nordisk also confirms that the app advises patients to help them find the correct insulin doses.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.